nach oben

Erschienen in:

01.04.2012 | Professional Issues

Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors

verfasst von: Bronson D. Riley, Julie O. Culver, Cécile Skrzynia, Leigha A. Senter, June A. Peters, Josephine W. Costalas, Faith Callif-Daley, Sherry C. Grumet, Katherine S. Hunt, Rebecca S. Nagy, Wendy C. McKinnon, Nancie M. Petrucelli, Robin L. Bennett, Angela M. Trepanier

Erschienen in: Journal of Genetic Counseling | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Updated from their original publication in 2004, these cancer genetic counseling recommendations describe the medical, psychosocial, and ethical ramifications of counseling at-risk individuals through genetic cancer risk assessment with or without genetic testing. They were developed by members of the Practice Issues Subcommittee of the National Society of Genetic Counselors Familial Cancer Risk Counseling Special Interest Group. The information contained in this document is derived from extensive review of the current literature on cancer genetic risk assessment and counseling as well as the personal expertise of genetic counselors specializing in cancer genetics. The recommendations are intended to provide information about the process of genetic counseling and risk assessment for hereditary cancer disorders rather than specific information about individual syndromes. Essential components include the intake, cancer risk assessment, genetic testing for an inherited cancer syndrome, informed consent, disclosure of genetic test results, and psychosocial assessment. These recommendations should not be construed as dictating an exclusive course of management, nor does use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider’s professional judgment based on the clinical circumstances of a client.

Amir, E., Freedman, O. C., Seruga, B., & Evans, D. G. (2010). Assessing women at high risk of breast cancer: a review of risk assessment models. Journal of the National Cancer Institute, 102(10), 680–691.PubMedCrossRef

American College of Medical Genetics (ACMG). (1995). Genetic Testing in Children and Adolescents, Points to Consider: Ethical, Legal and Psychosocial Implications. American Journal of Human Genetics, 57, 1233–1241.

American Society of Clinical Oncology (ASCO). (2003). ASCO policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406.CrossRef

American Society of Human Genetics (ASHG) Social Issues Subcommittee on Familial Disclosure. (1998). ASHG statement. Professional disclosure of familial genetic information. American Journal of Human Genetics, 62(2), 474–483.

Antoniou, A. C., Pharoah, P. P., Smith, P., et al. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580–90.PubMedPubMedCentralCrossRef

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 376(9737), 245–251.CrossRefPubMed

Baum, A., Friedman, A. L., & Zakowski, S. G. (1997). Stress and genetic testing for disease risk. Health Psychology, 16(1), 8–19.PubMedCrossRef

Bennett, R. L. (1999). The practical guide to the genetic family history. New York: Wiley.CrossRef

Bennett, R. L. (2010). The practical guide to the genetic family history (2nd ed.). Hoboken: Wiley-Blackwell.CrossRef

Bennett, R. L., French, K. S., Resta, R. G., & Doyle, D. L. (2008). Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 17(5), 424–433.PubMedCrossRef

Braithwaite, D., Emery, J., Walter, F., Prevost, A. T., & Sutton, S. (2006). Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Familial Cancer, 5(1), 61–75.PubMedCrossRef

Brown, K. L., Moglia, D. M., & Grumet, S. (2006). Genetic counseling for breast cancer risk: general concepts, challenging themes and future directions. Breast Disease, 27, 69–96.PubMedCrossRef

Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology, 28(3), 375–379.PubMedCrossRef

Chivers-Seymour, K., Addington-Hall, J., Lucassen, A., & Foster, C. (2010). What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. Journal of Genetic Counseling, 19(4), 330–342.PubMedCrossRef

Claus, E. B., Risch, N., & Thompson, W. D. (1993). The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment, 28(2), 115–20.PubMedCrossRef

Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., (1997). BRCA1 mutations in women attending clinics that evaluate breast cancer risk. The New England Journal of Medicine 336, 1409–1415.PubMedCrossRef

Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B., & Nash, J. (1997). Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychology, 16(1), 63–72.PubMedCrossRef

Culver, J. O., Lowstuter, K., & Bowling, L. (2006). Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Disease, 27, 5–20.PubMedCrossRef

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Journal of the American Medical Association, 304(9), 967–975.PubMedCrossRef

Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., Kalkbrenner, K. J., et al. (2000). Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. Journal of Clinical Oncology, 18(10), 2135–2142.PubMedCrossRef

Edwards, A., Gray, J., Clarke, A., Dundon, J., Elwyn, G., Gaff, C., et al. (2008). Interventions to improve risk communication in clinical genetics: systematic review. Patient Education and Counseling, 71(1), 4–25.PubMedCrossRef

Eng, C., Hampel, H., & de la Chapelle, A. (2001). Genetic testing for cancer predisposition. Annual Review of Medicine, 52, 371–400.PubMedCrossRef

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.CrossRef

Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006). Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. Journal of Medical Genetics, 43, 289–294.PubMedCrossRef

Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute, 90(18), 1371–1388.CrossRefPubMed

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123–134.PubMedCrossRef

Forrest, L. E., Burke, J., Bacic, S., et al. (2008). Increased genetic counseling support improves communication of genetic information in families. Genetics in Medicine, 10(3), 167–72.PubMedCrossRef

Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood M. E., Mullineau L., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology 16, 2417–2425.PubMedCrossRef

Gail, M. H., Brinton, L. A., Byar, D. P., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81(24), 1879–86.CrossRefPubMed

Gallo, A. M., Angst, D. B., & Knafl, K. A. (2009). Disclosure of genetic information within families. The American Journal of Nursing, 109(4), 65–69.PubMedPubMedCentralCrossRef

Gaff, L., & Bylund, C. (Eds.). (2010). Family communication about genetics. New York: Oxford University Press.

Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B. B., Wilfond, B., et al. (1997). Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. Journal of the American Medical Association, 277(18), 1467–1474.PubMedCrossRef

Hampel, H., Sweet, K., Westman, J. A., Offit, K., & Eng, C. (2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. Journal of Medical Genetics, 41(2), 81–91.PubMedPubMedCentralCrossRef

Hudson, K., Javitt, G., Burke, W., Byers, P. A., & Society of Human Genetics (ASHG) Social Issues Committee. (2007). ASHG Statement* on direct-to-consumer genetic testing in the United States. Journal of Obstetrics and Gynecology, 110(6), 1392–1395.PubMedCrossRef

Jenkins, J., Calzone, K. A., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine, 9(8), 487–95.PubMedCrossRef

Kenen, R. H., Shapiro, P. J., Friedman, S., & Coyne, J. C. (2007). Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psycho-Oncology, 16(8), 763–771.PubMedCrossRef

Kloos, R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., et al. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19(6), 565–612.PubMedCrossRef

Koehly, L. M., Peters, J. A., Kenen, R., Hoskins, L. M., Ersig, A. L., Kuhn, N. R., et al. (2009). Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. American Journal of Public Health, 99(12), 2203–2209.PubMedPubMedCentralCrossRef

Konstantopoulou, I., Pertesi, M., Fostira, F., Grivas, A., & Yannoukakos, D. (2009). Hereditary cancer predisposition syndromes and preimplantation genetic diagnosis: where are we now? Journal of Balkan Union Oncology, 14(Suppl 1), S187–192.

Lerman, C., Biesecker, B., Benkendorf, J. L., Kerner, J., Gomez-Caminero, A., Hughes, C., & Reed, M. M. (1997). Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. Journal of the National Cancer Institute, 89(2), 148–157.PubMedCrossRef

Ligtenberg, M. J., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nature Genetics, 41(1), 112–117.PubMedCrossRef

Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. Journal of the American Medical Association, 296(12), 1507–17.PubMedCrossRef

Lindor, N. M., McMaster, M. L., Lindor, C. J., & Greene, M. H. (2008). Concise handbook of familial cancer susceptibility syndromes—second edition. Journal of the National Cancer Institute. Monographs, 38, 1–93.

Lindor, N. M., Johnson, K. J., Harvey, H., Pankratz, V. S., Domchek, S. M., Hunt, K., Wilson, M., Smith, C. S., & Couch, F. (2010). Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Familial Cancer, 9, 405–402.CrossRef

McKinnon, W., Naud, S., Ashikaga, T., Colletti, R., & Wood, M. (2007). Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. Journal of Genetic Counseling, 16(4), 433–456.PubMedCrossRef

Meiser, B. (2005). Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology, 14(12), 1060–1074.PubMedCrossRef

Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328–35.PubMedCrossRef

National Cancer Institute (NCI) (2010). PDQ® Cancer Genetics Risk Assessment and Counseling. Retrieved from https://doi.org/cancer.gov/cancertopics/pdq/genetics/risk-assessment-andcounseling/HealthProfessional.

National Comprehensive Cancer Network (NCCN) 2 (2011) NCCN Clinical Practice Guidelines in Oncology, Colorectal Cancer Screening. Retrieved from https://doi.org/www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf.

National Society of Genetic Counselors. (2007). NSGC Position Statement: Direct to Consumer Genetic Testing. Retrieved from https://doi.org/www.nsgc.org/Advocacy/PositionStatements/tabid/107/Default.aspx.

Nelson, R. M., Botkjin, J. R., Kodish, E. D., Levetown, M., Truman, J. T., Wilfond, B. S., et al. (2001). Ethical issues with genetic testing in pediatrics. Pediatrics, 107(6), 1451–1455.CrossRef

Offit, K., Kohut, K., Clagett, B., Wadsworth, E. A., Lafaro, K. J., Cummings, S., et al. (2006). Cancer genetic testing and assisted reproduction. Journal of Clinical Oncology, 24(29), 4775–4782.PubMedCrossRef

Offit, K., Groeger, E., Turner, S., Wadworth, E. A., & Weiser, M. A. (2004). The “duty to warn” a patient’s family members about hereditary disease risks. Journal of the American Medical Association, 292(12), 1469–73.PubMedCrossRef

Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62(1), 145–58.PubMedPubMedCentralCrossRef

Patenaude, A. F., & Juliean-Reynier, C. (2008). Cancer genetic testing: current and emerging issues. Psycho-Oncology, 17(8), 733–736.PubMedCrossRef

Pieterse, A. H., Ausems, M. G., Van Dulmen, A. M., Beemer, F. A., & Bensing, J. M. (2005). Initial cancer genetic counseling consultation: change in counselees’ cognitions and anxiety, and association with addressing their needs and preferences. American Genetics in Medicine, 137(1), 27–35.CrossRef

Pieterse, A. H., van Dulmen, A. M., Beemer, F. A., Bensing, J. M., & Ausems, M. G. (2007). Cancer genetic counseling: communication and counselees’ post-visit satisfaction, cognitions, anxiety, and needs fulfillment. Journal of Genetic Counseling, 16(1), 85–96.PubMedPubMedCentralCrossRef

Pilarski, R. (2009). Cowden syndrome: a critical review of the clinical literature. Journal of Genetic Counseling, 18(1), 13–27.PubMedCrossRef

Quillin, J. M., Bodurtha, J. N., Siminoff, L. A., & Smith, T. J. (2010). Exploring hereditary cancer among dying cancer patients-a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. Journal of Genetic Counseling, 19(5), 497–525.PubMedPubMedCentralCrossRef

Qureshi N, Wilson, B., Santaguida P., Carroll J., Allanson J., Ruiz Culebro C., et al. (2007). Collection and Use of Cancer Family History in Primary Care. Evidence Report/Technology Assessment No. 159 (prepared by the McMaster University Evidence-based Practice Center, under Contract No. 290-02-0020). Rockville, MD: Agency for Healthcare Research and Quality, AHRQ Publication No. 08-E001.

Rich, E. C., Burke, W., Heaton, C. J., Haga, S., Pinsky, L., Short, M. P., et al. (2004). Reconsidering the family history in primary care. Journal of General Internal Medicine, 19(3), 273–280.PubMedPubMedCentralCrossRef

Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.PubMedCrossRef

Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology, 28(20), 3219–3226.PubMedPubMedCentralCrossRef

Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., American Cancer Society Breast Cancer Advisory Group, et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. A Cancer Journal for Clinicians, 57(2), 75–89.CrossRef

Schneider, K. A. (2002). Counseling about cancer: Strategies for genetic counseling (2nd ed.). New York: Wiley-Liss.

Schneider, K. A., DiGianni, L. M., Patenaude, A. F., Klar, N., Stopfer, J. E., Calzone, K. A., et al. (2004). Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genetic Testing and Molecular Biomarkers, 8(3), 222–8.CrossRef

Schneider, K. A., Chittenden, A. B., Branda, K. J., Keenan, M. A., Joffe, S., Patenaude, A. F., et al. (2006). Ethical issues in cancer genetics: whose information is it? Journal of Genetic Counseling, 15(6), 491–503.CrossRefPubMed

Sivell, S., Iredale, R., Gray, J., & Coles, B. (2007). Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database of Systematic Reviews(2), CD003721.

Spits, C., De Rycke, M., Van Ranst, N., Verpoest, W., Lissens, W., Van Steirteghem, A., et al. (2007). Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenatal Diagnosis, 27(5), 447–56.PubMedCrossRef

Stultiens, B. P., Nys, H., Cassiman, J. J., & Dierickx, K. (2006). Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clinical Genetics, 70, 374–381.PubMedCrossRef

Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.CrossRefPubMed

Trepanier, A., Allain, D., & Cohen S. (2011). Assessing the use of various service delivery models in cancer genetics. Abstract 366. American College of Medical Genetics.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 376(9737), 235–244.PubMedCrossRef

Tyrer, J., Duffy, S. W., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23(7), 1111–30.CrossRefPubMed

United States Preventive Services Task Force (USPSTF). (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 143(5), 355–61.CrossRef

Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–8.PubMedCrossRef

Weissman, S. M., Bellcross, C., Bittner, C. C., Freivogel, M. E., Haidle, J. L., Kaurah, P., et al. (2011). Genetic counseling considerations in the evaluation of families for Lynch syndrome- a review. Journal of Genetic Counseling, 20(1), 5–19.PubMedCrossRef

Weitzel, J. N., Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, J. O., Blazer, K. R., et al. (2007). Limited family structure and BRCA gene mutation status in single cases of breast cancer. Journal of the American Medical Association, 297(23), 2587–2595.PubMedCrossRef

Wham, D., Vu, T., Chan-Smutko, G., Kobelka, C., Urbauer, D., & Heald, B. (2010). Assessment of clinical practices among cancer genetic counselors. Familial Cancer, 9(3), 459–468.PubMedCrossRef

Titel: Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors
verfasst von: Bronson D. Riley
Julie O. Culver
Cécile Skrzynia
Leigha A. Senter
June A. Peters
Josephine W. Costalas
Faith Callif-Daley
Sherry C. Grumet
Katherine S. Hunt
Rebecca S. Nagy
Wendy C. McKinnon
Nancie M. Petrucelli
Robin L. Bennett
Angela M. Trepanier
Publikationsdatum: 01.04.2012
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 2/2012
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-011-9462-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

A Serendipitous Invitation

Evaluating a Session—Punitive vs. Reflective

Rebuilding My Fortress

Losing Sight

Taking Advantage of a Unique Opportunity: A Genetic Counseling Fellowship in Lysosomal Storage Disorders

A Couple’s Devastating Journey & My Development as a Genetic Counselor

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie